We can check with your insurance to see if it will cover Pulmozyme.

Benefits Investigation

A benefits investigation will help determine whether your insurance will cover Pulmozyme and which financial assistance options may be right for you. Pulmozyme Access Solutions will conduct the benefits investigation. Pulmozyme Access Solutions works with you, your doctor's office, your health insurance plan and your specialty pharmacy to help you get your prescribed Pulmozyme.

To get started:

  1. Complete the Patient Consent Form, which is available in English and Spanish, below:
  2. Once you have completed the Patient Consent Form, please inform your doctor's office and let them know that you are applying for assistance with Pulmozyme Access Solutions. Your doctor will have to complete another form called the Prescriber Service Form. Both forms are required. No eligibility determination will be made until a completed Patient Consent Form and Prescriber Service Form have been received.

What to expect next:

  • The request will be processed within 5 business days upon receipt of both required forms
  • You and your provider will be contacted to discuss the application outcome and any next steps

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Contact Us

Questions? Contact Access Solutions

Call 866-422-2377 (Mon.–Fri., 6AM–5PM PST)

  • Benefits investigation: A review of how your health insurance plan covers a medicine or treatment your doctor has prescribed.

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.